Antiviral treatment for patients with hepatitis C virus (HCV) infection has undergone a massive revolution in the last five years, since the development of HCV direct‐acting antiviral agents (DAAs). Several combinations of DAAs regimens have been reported to have a higher effectiveness and tolerability compared to IFN‐based regimens. The first available DAAs were the HCV NS3/4A protease inhibitors, telaprevir and boceprevir. These newer HCV medications have been found to have a much greater response rate than the classic therapy. This has drawn the attention of specialist doctors, including dermatologists. In fact, in 2014, Klujszo et al. noticed the link between skin rashes and protease inhibitors during HCV therapy, which has been described in around 21% of patients using telaprevir. The high rate of adverse effects associated with this therapy was a common cause of withdrawal, limiting the possibility of achieving sustained virologic response in HCV‐infected patients. It has not been proven that newer protease inhibitors such as boceprevir increase the risk of skin rashes, as Carrascosa et al. explain in their article. There is a new combination of drugs, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Viekirax® and Exviera®) that is worth discussing, following our experience with a patient who had a generalized
International Journal of Dermatology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud